• 1
    Mabuchi H, Sakai T, Sakai Y et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compaction and cholestne. N Engl J Med 1983;308:60913.
  • 2
    Witztum JL, Simmons D, Steinberg D et al. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation 1989;79:1628.
  • 3
    Mabuchi H. Use of LDL-apheresis in the management of familial hypercholesterolemia. Curr Opin Lipidol 1990;1:437.
  • 4
    Kajinami K, Mabuchi H. Therapeutic effects of LDL apheresis in the prevention of arherosclerosis. Curr Opin Lipidol 1999;9:4016.
  • 5
    Barbagallo CM, Averna MR, DiMarco T et al. Effectiveness of cascade filtration plasmapheresis in two patients affected by familial Hypercholesterolemia. J Clin Apher 1995;10:96100.
  • 6
    Hans C, Geiss KG, Parhofer MG, Donner P. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther Apher 2002;3:199202.
  • 7
    Hurlbert SN, Mattos MA, Henretta JP et al. Long-term patency rates, complications and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis Access: a prospective study that compares Impra versus Gore-Tex grafts. Cardiovasc Surg 1998;6:6526.
  • 8
    Nicholson JF, Pesce MA. Laboratory medicine, drug therapy, and reference tables. In: BehrmanRE, KliegmanRM, JensonHB, eds. Nelson Textbook of Pediatrics. Philadelphia, PA: Saunders, 2000;2202.
  • 9
    Uany R, Vega GL, Grundy SM, Bilheimer DW. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentration or turnover. J Pediatr 1998;113:38392.
  • 10
    Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. Metabolic and Molecular Bases of Inherited Disease, 7nd edn. New York: Mc-Graw Hill, 1995;19812030.
  • 11
    Starch TJ, Deckelbaum RJ. Evaluation of hypercholesterolemia in childhood. Pediatr Rev 1996;17:947.
  • 12
    Shafiq N, Bhasin B, Pattanaik S et al. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Ther 2007;45:54855.
  • 13
    King ME, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med 1980;302:14579.
  • 14
    Stoffel W, Greve V, Borberg H. Application of specific extracorporeal removel of low density lipoprotein in familial hypercholesterolemia. Lancet 1981;2:10057.
  • 15
    Godehardt E, Messner H, Wallstab UH. Extracorporeal LDL cholesterol elimination by membrane differential filtration. A retrospective analysis of 1702 treatments. In: GottoAM, ManciniM, RichterWO, SchwandtP, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease, 1st edn. Basel: Karger, 1993;20820.
  • 16
    Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998;82:1489585.
  • 17
    Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher 1997;1:2428.
  • 18
    Hummelsheim T, Borberg H, Brunner R, Oette K. Acute changes of hemorheological parameters by LDL apheresis: specific immunoadsorption versus cascade filtration. Infusionsther Transfusionsmed 1995;22:426.
  • 19
    Karabay O, Bak M, Silistreli E et al. Effect of adventitial dissection in brachiobasilic arteriovenous fistulae opened in children as vascular access for hemodialysis on patency and maturation of the fistulae. J Investig Med 2004;52:3304.